Background: For individuals with multiple myeloma (MM) and Hodgkin's lymphoma relapsed or recurrent cases (R/R-HL) who fulfil transplantation criteria and are chemo-sensitive to salvage therapy, autologous haematopoietic stem cell transplantation (HSCT) is one of the conventional therapeutic choices. HSCT has shown to be a safe and effective therapy when used in inpatient settings, but it may also be used in outpatient settings. Methodology: The study involves retrospective data collection of patients who underwent auto-HSCT in a cottage ward, a less intensive area with good air quality and confirmed diagnosis of MM and HL. Results: Six patients received auto HSCT in the cottage ward, a less intensive area with good air quality,2 R/R-HL and 4 MM at our institution. The patients subjected to HSCT had a median age of 57.5 years for MM and 26 years for HL, respectively. The MM patients were presented at the time of admission with features such as stage II and stage III, 50% each, extensive bone involvement in 100%, and normal cytogenetics in 50% of the patients. The HL patients, at the time of admission were in Stage III according to the Ann Arbor classification with neither B-symptoms nor bulky disease. A 100-day survival rate of 100% was achieved in patients who underwent AutoHSCT in the cottage ward, a less intensive area with good air quality. Conclusion: Patients with MM and HL with standard risk can benefit from auto HSCT in a cottage ward, a less intensive area with good air quality, which is safe, effective, economical and feasible. Furthermore, HSCT in a cottage ward, a less intensive area with good air quality, can result in better patient compliance and satisfaction, swifter recovery and better outcomes. Keywords: Multiple myeloma; Hodgkin lymphoma; Autologous hematopoietic stem cell transplantation; Non-cryopreservation; Outpatient transplantation